MentalHealthDaily

Comparison of Brexipiprazole vs. Aripiprazole for Treatment-Resistant Depression (2024 Study)

by GLOOM

Antidepressant-resistant major depressive disorder (AR-MDD) poses significant challenges in psychiatric treatment. Antipsychotics like aripiprazole (ARI) and brexpiprazole (BRE) have emerged as effective adjunct therapies that may be more tolerable than older antipsychotics. Highlights: Both Brexipiprazole and Aripiprazole demonstrated better efficacy than placebo in treating AR-MDD in Japanese patients. Brexipiprazole showed a higher discontinuation rate due …

Quetiapine Dosing for Depression Optimized with XGBoost Algorithm (2024 Study)

by GLOOM

Depression is a globally pervasive mental illness that often requires complex treatment strategies. One such strategy involves the use of Quetiapine, an antipsychotic medication, as an augmentation to antidepressants. However, determining the optimal dose of Quetiapine is challenging due to individual variability. A recent study utilizes machine learning techniques to develop a predictive model for …

Metformin Prevents Antipsychotic-Induced Weight Gain: A Saudi Study Finds

by GLOOM

Research suggests that metformin may reduce weight gain associated with antipsychotic medications. Key facts: Antipsychotics are linked to weight gain, especially clozapine and olanzapine. Metformin may counteract antipsychotic-induced weight gain through effects on insulin resistance and appetite. Study found metformin reduced mean weight gain on antipsychotics from 2.5 kg to -0.04 kg. Younger patients ages …

Rexulti (Brexpiprazole) Withdrawal Symptoms: What You Should Know

by GLOOM

Rexulti (Brexpiprazole) is an atypical antipsychotic that is most commonly utilized as a pharmacologic intervention for the management of schizophrenia, and in some cases, as an add-on (adjunct) treatment for refractory major depressive disorder. Throughout the central nervous system, the medication exerts neurophysiologic effects across dopaminergic, serotonergic, noradrenergic, and histaminergic targets. Receptor sites most targeted …

Vraylar (Cariprazine) Withdrawal Symptoms: What To Expect After Discontinuation

by GLOOM

Vraylar (Cariprazine) is an atypical antipsychotic that is most frequently prescribed as a pharmacological intervention for schizophrenia and bipolar disorder. The medication functions predominantly as a: D3 and D2 receptor partial agonist, 5-HT2B receptor antagonist, and 5-HT1A partial agonist. To a less significant extent, Vraylar interacts with H1 receptors and 5-HT2A receptors as an antagonist. …

Vraylar (Cariprazine) Side Effects & Adverse Reactions

by GLOOM

Vraylar (Cariprazine), is an atypical antipsychotic medication approved in 2015 by the FDA for the treatment of schizophrenia and bipolar disorder. Occasionally, Vraylar is also prescribed as an adjunct for treatment-resistant depression and off-label for anxiety disorders. Although Vraylar is marketed as an improvement over older atypical antipsychotic medications in terms of efficacy and tolerability, …

Vraylar (Cariprazine) & Weight Gain vs. Loss: What You Should Know

by GLOOM

Vraylar (Cariprazine), also sold under the name Reagila [in European countries], is an atypical antipsychotic developed by the pharmaceutical company Allergan. In 2015, Vraylar received FDA approval for the treatment of schizophrenia and mania associated with bipolar disorder. From a pharmacodynamic perspective, Vraylar functions predominantly as a partial agonist at D3 and D2 dopamine receptors, …